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ABSTRACT (150 words) 
The incidence of cancer is continuing to rise and risk-tailored early diagnostic or primary 
prevention strategies are urgently required. Risk predictive tests should (i) integrate both 
genetic and non-genetic factors captured by an omics-technology that is biologically stable 
and technically reproducible, (ii) derive a score from easily accessible biological samples that 
act as surrogate for the organ in question and (iii) allow the efficacy of risk reducing measures 
to be monitored. Substantial evidence has accumulated suggesting that the epigenome and 
in particular DNA methylation (DNAme) based tests may meet these requirements. However, 
developing and implementing DNAme based risk predictive tests pose considerable 
challenges. Cell-type specificity of DNAme and cell-type heterogeneity in easily accessible 
surrogate cells requires novel methods to account for confounding issues. Engagement of 
the scientific community with healthcare professionals, policy makers and the public is 
required to identify and address the organisational, ethical, legal, social and economic 
challenges. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TEXT (6316 words) 
 
Introduction 
Cancer is a leading cause of mortality worldwide, accounting for 14.1 million new cases and 
8.2 million deaths in 20121. It has been estimated that global cancer burden will increase 
yearly to 20.3 million new cases and 13.2 million deaths by 20302. Environmental, 
behavioural and life style risk factors3, genetic predisposition, and acquisition of random 
mutations can lead to cancer development3-5. Prevention and early detection remain the key 
interventions to reduce global cancer burden.  
 
Almost all cancers occur against a background of individual risk factors including 
environmental, lifestyle, reproductive and heritable genetic factors. High penetrance genetic 
mutations are rare in the population and account for only a small proportion of cases. 
Nevertheless, most common cancers have a heritable component spread across thousands 
of common germline variants each conferring small risk increments6. Genome-wide 
association studies have revealed common variants that explain a small fraction of heritability 
(Table 1). The remainder of the heritability may eventually be found through ever larger 
association studies, but more immediately it may be effectuated through -omics intermediates 
(e.g. epigenomics) that have stronger, more direct effects on cancer occurrence7. 
 
Considering the heterogeneity of risk in the population, tailoring preventive and early 
detection interventions to an individual’s risk level could improve the efficacy of population-
based programmes in prevention and early detection of cancer8. In the prostate cancer 
setting, for example, targeting screening to men at higher than population average risk could 
reduce the proportion of men likely to be over-diagnosed and, consequently, over-treated9,10. 
 
Currently, several biomarker tests and complementary statistical models have been 
developed to predict cancer risk (Table 2). With notable exceptions, such as a model based 
on HPV-DNA testing to predict a precursor of cervical cancer (CIN2+)11, most risk models 
include only epidemiological factors. The discriminative ability of these models in 
separating low from high risk subjects is modest, as expressed by the area under the 
Receiver Operating Characteristic curve (ROC AUC, a measure of discriminatory accuracy 
of a model and the probability that a test correctly identifies an individual who will develop 
the disease from a pair of whom one will be affected and one will remain unaffected; AUC 
values range from 0.5 which is a total lack of discrimination to 1.0 which is a perfect 
discrimination). In addition, current models do not typically differentiate in terms of 
prognosis, which is vital for tailored screening and primary prevention (i.e. early detection 
or prevention of those cancers which would otherwise lead to death). 
 
A predictive test should (i) integrate genetic and non-genetic factors captured by an 
omics-technology that is both biologically stable and technically reproducible (ii) derive a risk 
prediction score, using easily accessible tissues, that is relevant for cancer development 
or is able to capture risk-inducing factors and ideally (iii) has the added potential of enabling 
monitoring of the efficacy of potential risk reducing measures. The basis of this strategy 
is drawn from the discipline of cardiovascular medicine. Risk prediction and tailored 
chemoprevention for non-symptomatic individuals have been fundamental in the dramatic 
reduction in mortality from myocardial infarction and stroke12. The cardiovascular community 
has accepted the principle that freedom from symptoms does not equate to a guarantee of 
health and the use of ‘surrogate end points’ was central to their success. Both blood pressure 
and cholesterol concentration can (i) be easily assessed by non-invasive measures, (ii) act 
as surrogates for an individual’s interaction with environmental factors (i.e. stress, nutrition, 
smoking, absence of physical exercise, etc.) and (iii) are key components of multivariable risk 
algorithms13. It is also well known that phenotypic variability between different populations 
takes place both at the genetic and epigenetic levels, indicating that epigenetic modification 
substantially contributes to natural human variation14. Correspondingly, we propose a novel 
population-based screening methodology that relies upon epigenetics as a surrogate marker 
for risk prediction.  
We will discuss the potential of DNA methylation (DNAme) markers to predict the risk of 
developing specific cancers and highlight the importance of Epigenome-Wide Association 
Studies (EWAS). Since epigenetic changes are tissue specific one of the biggest challenges 
is to identify easily accessible surrogate cells and develop algorithms to assess cell 
heterogeneity. In addition, we will address the legal, ethical and economic challenges along 
with other aspects associated with the implementation of epigenetic tests into the clinical and 
population screening / public health arena.  
 
Epigenetics in cancer development: Epigenetic traits can be mitotically and also 
meiotically (i.e. transgenerationally) inherited, but unlike genetics they are not conferred by 
the sequence of bases defining the genetic code. Epigenetics is rather defined by a collective 
of dynamic processes that fine tune and regulate gene expression. As such epigenetics can 
be considered the ‘editor’ of the genome, affording our cells their identity and providing 
genomic plasticity, particularly at key time points in early development15, in the maintenance 
of adult select tissues and in response to lifetime environmental exposures. Three interacting 
components – DNA methylation (DNAme), histone modification and non-coding RNA – are 
integral to epigenetic regulation and function in a tissue specific manner. Methylation of the 
C5 position of cytosines within the CpG dinucleotide (DNAme) context is technically and 
biologically the most stable component of the epigenome and is modified both by inherent 
genetic components as well as all non-heritable factors which shape living organisms16. 
Nevertheless CpGs represent at best ~2% of the spatial genome and are notably 
concentrated within short stretches of DNA in gene promoters known as ‘CpG islands’. In 
cancer tissue hypermethylation of CpG islands against a background of global 
hypomethylation, both associated with skewed genetic expression, are hallmarks of 
epigenetic modulation witnessed across a multitude of cancer types.  
Over recent years it has become evident that epigenetic mis-programming constitutes a core 
component of cancer initiation and progression. One of the key involvements of epigenetic 
de-regulation in cancer development has been the observation that DNA regions, that under 
normal conditions are specifically marked and transiently silenced by Polycomb-Group (PCG) 
proteins in stem cells, become methylated and completely silenced in cancer17-19. This led to 
the proposal of an ‘epigenetic stem cell model’ of cancer whereby cells acquiring DNA 
methylation at (Polycomb-Group Target (PCGT) genes become erroneously de-differentiated 
and subsequently prone to somatic mutations. Such targeted DNAme can be mediated by a 
specific non-coding RNA (e.g. HOTAIR20-22) that interacts with Polycomb Repressive 
Complex 2 (PRC2). HOTAIR links the PRC2 component EZH2 (Enhancer of zeste homolog 
2), a histone-lysine N-methyltransferase enzyme, to histone H3 in order to catalyse the 
addition of methyl groups to lysine 27 (H3K27) which eventually leads to DNAme in the 
corresponding region23-25 (Figure 1). Smoking-related methylation changes (which 
specifically affect PCGT sites26) in blood cells survive for a long time after smoking 
cessation26-28, far longer than the lifetime of differentiated blood cells, again strongly 
supporting the view that environmentally-triggered epigenetic alterations are most probably 
embedded in stem cells. 
There is ample proof demonstrating that PCGT methylation is a prerequisite for cells to 
transform into cancer cells23,24,29-31 and that PCGT methylation seems to accumulate in stem 
cells as a function of cell divisions which is strongly associated with cancer risk32-34. The 
proportion to which epigenetic and genetic alterations contribute to cancer formation has not 
been assessed, but it has become clear that only stem cells (which are epigenetically 
determined) have the capacity to survive oncogene-induced substantial DNA damage35 
(Figure 2A). Recent research demonstrates that epigenetic contribution to cancer 
progression is far more complex than originally appreciated. Studies have shown that PCGT 
methylation in cells other than those from which the cancer originates can influence cancer 
development. For example, HAND2, a gene located downstream of the progesterone 
pathway, is highly expressed during the luteal phase in the endometrial stroma and affects 
the attenuation of oestrogen-mediated paracrine proliferation signals from the stroma that 
target endometrial epithelial cells36. HAND2 methylation and silencing in the normal 
endometrial stroma leads to functional oestrogen dominance that results in complex atypical 
hyperplasia of the endometrium37 (Figure 2B) of which approximately 50% progress to a full 
blown cancer38. Observational evidence in other cancer entities support the view that 
epigenetic changes in the morphological normal stroma contribute to cancer initiation and 
progression39-43. Although not yet experimentally proven it is tempting to speculate that 
epigenetic alterations in cell-nonautonomous contributors to cancer development (e.g. 
immune cells and organs which provide endocrine signals) play important roles. Early 
evidence indicating that PCGT methylation (i.e. HOX gene family methylation in normal 
endometrium) is strongly associated with the presence of a cancer in an anatomically distant 
organ (i.e. ovarian cancer)44 provided preliminary proof of concept suggesting that DNAme 
analyses in more easily accessible cells could be used to predict the risk of developing 
cancer. 
Besides methylation at PCGT, there are a variety of other examples describing how 
epigenetic alterations contribute to cancer development. A large number of trait-associated 
genetic variants have, for instance, been shown to affect DNAme levels at different CpG sites 
including binding sites of a variety of transcription factors (such as NFKB1 and CTCF) which 
are known to be involved in cancer formation7. The importance of this mechanism is 
strengthened by the fact that those CpG sites which demonstrate aberrant DNAme in 
colorectal cancer are substantially enriched for those genetic variants which are discovered 
by genome-wide association studies comparing individuals with and without colorectal 
cancer45. The fact that methylated cytosines are substantially more prone to undergo 
spontaneous deamination46 and mutations at CpG sites are frequently observed in cancer47,48 
provides another example of how aberrant DNAme contributes to cancer development. 
 
 
Effects of cancer-predisposing factors on the epigenome: 
The epigenome, specifically DNAme, is shaped by both heritable and non-heritable factors 
which are also known to have a substantial impact on cancer development (Figure 1) and 
therefore hold great promise as an objective surrogate for these factors. 
 
Genome-Epigenome interaction: 
The mechanisms by which inherited common sequence variations lead to cancer are largely 
uncharted, but may become manifest through their impact on the epigenome in three different 
ways: 
o Cell autonomous impact - genetic variants impact directly on the epigenome: Allele-
specific methylation may be associated with methylation quantitative trait loci (meQTL), 
single nucleotide polymorphisms (SNPs) that associate with the methylation status of 
specific sites or entire regions7,49-51. To date, numerous meQTL have been discovered 
utilising novel tools52.  While efforts to relate meQTL to disease processes are still at an 
early stage, DNA methylation represents one plausible downstream effect of SNPs on 
disease that may be directly measured to achieve greater accuracy in risk modelling. 
This is supported by the finding that regions at previously reported and, as-yet, 
unidentified cancer risk polymorphisms show aberrant DNA methylation53. 
o Cell non-autonomous impact: High-penetrance germline mutations (e.g. BRCA 
mutations) modulate endocrine factors54-59 (e.g. higher oestrogen and progesterone 
production in the ovary) which then impact specifically on the epigenome of cells 
receptive to these signals, in the case of oestrogen, tubal or breast epithelial cells60. 
These changes are typically tissue type-dependent. 
o “Genetic environmental filter” impact: The activity of enzymes involved in the metabolism 
of exogenous substances is largely determined by inherited genetic polymorphisms and 
will determine, in part, the effect of environmental exposures on the epigenetic makeup 
as evidenced by, for example, CYP2A6 genotype and nicotine/cotinine clearances61 and 
the linear relationship between serum cotinine, a major metabolite of nicotine, and DNA 
methylation62. 
 
Transgenerational inheritance: 
The phenomenon of transmitting information from one generation to the next affecting the 
traits of offspring without altering the germline sequence of the nucleotides (i.e. 
epigenetically) has been repeatedly demonstrated63,64. For example, access to food65 and 
exposure to smoking66 early in life have repeatedly been demonstrated to impact on future 
generation’s phenotypes. There is substantial evidence that DNAme of the POMC gene is 
transmitted via the paternal germline leading to an increased risk of developing obesity later 
in life67 and that parental diet can affect cholesterol and lipid metabolism in offsprings68. It is 
well established that body mass index (BMI) is strongly associated with human cancer risk69 
and obesity itself also seems to trigger epigenetic alterations70.  
 
In-utero environment: 
Many women who were exposed in utero to diethylstilbestrol (DES), a synthetic non-steroidal 
oestrogen provided to their mothers, have a substantially elevated risk of cervical 
intraepithelial neoplasia, breast cancer and clear cell vaginal cancer decades later71. DES 
upregulates HOTAIR72 and leads to hypermethylation of HOXA1073, a key gene involved in 
female genital tract development, in DES-exposed offspring. Together these findings suggest 
that DES’ carcinogenic potential is mediated via epigenetic mechanisms. Effects of foetal 
exposure to other endocrine-disrupting chemicals including Bisphenol A have demonstrated 
carcinogenic effects to varying degrees74 and are at least, in part, epigenetically transmitted75. 
 
Obesity: 
Obesity is thought to have a substantial and direct impact on the epigenome70. The epigenetic 
effects are reflected in a program for shared drivers for cancer progression in organs such 
as the endometrium76, liver77, breast78 and colon79, the very same organs at increased risk of 
developing cancer in obese individuals80. Obesity, is likely to cause chronic low-grade 
inflammation81, and potentially mediates its impact on DNA methylation via oxidative damage 
induced formation and re-localisation of epigenetic silencing complexes to stem cell 
PCGTs82. These processes are likely to differ among obese individuals with identical BMIs in 
accordance with their innate environmental response70. Habitual changes that lead to a 
reduction of obesity (i.e. caloric restriction) substantially slows the epigenetic clock83,84 with a 
resultant decrease in cancer risk85-87.  
 
Smoking: 
Exposure to cigarette smoke triggers striking epigenetic changes. Hypomethylation of genes 
involved in toxin response pathways such as AHRR, CYP1A1, and CYP1B126,88-91 has been 
observed across different tissues though most of the evidence comes from blood and buccal 
tissue. Since hypomethylation of these genes is not consistently observed in cancer26 these 
epigenetic changes may not be causally involved in cancer progression. Smoking-triggered 
hypermethylation of genes bivalently marked in human stem cells (i.e. PCGT genes) is 
predominantly observed in epithelial (e.g. buccal) cells26. A smoking index constructed using 
these hypermethylated sites is highly efficient in discriminating between normal and 
cancerous tissues26. 
 
Microbiome and virome impact on the host epigenome: 
Infections with certain bacteria or viruses have been identified as strong risk factors for 
specific human cancers92 and alterations in microbiota may contribute to human 
carcinogenesis93 . Mono- or polymicrobial factors can cause changes in the human host 
mediated through genetics, epithelial injury, immune system function and/or 
inflammation93. Microbiota have also been shown to affect oestrogen metabolism94. The 
microbiome appears to affect the epigenome through DNAme dependent pathways in the 
host95. For example, gut bacteria can provide epigenetically active metabolites essential 
for DNAme such as folate, butyrate and acetate, as well as enzymes and cofactors for 
epigenetic processes94. 
 
Chronic inflammation: 
Some cancers develop due to chronic inflammatory insults96. Carcinogenesis associated with 
inflammatory bowel disease, reflux oesophagitis, pancreatitis or pelvic inflammatory disease 
converge at the level of the transcription factors nuclear factor-κB (NF-κB) and signal 
transducer and activator of transcription 3 (STAT3) which lead to epigenetic reprogramming 
in epithelial cells of the affected organ60,97-99. Again, the majority of genes affected by 
inflammation-mediated reprogramming are PCGT genes100,101. 
 
Hormones and DNAme: 
Absolute levels of hormones, dynamics over time (e.g. throughout the menstrual cycle) as 
well as relative levels across various hormones (e.g. oestrogen/progesterone balance) 
contribute to the cancer risk of hormone sensitive organs55,56,102-105. Steroid hormones are key 
regulators of genes involved in epigenetic programming (AID106, DNMTs, EZH2, etc.). 
Dramatic changes in the systemic hormonal environment – as for example during the 
menopause – lead to substantial epigenetic changes, which are in part, cell type specific107. 
In addition, proxy indicators for endogenous prenatal testosterone exposure (i.e. the 
anogenital distance108 or the ratio of digit length109) are associated with prostate cancer risk, 
consistent with the view that androgens also leave an epigenetic imprint which, after several 
decades, lead to a specific phenotype.  
 
Age: 
Age contributes to the cancer risk of a given tissue/organ in two ways: a cell-intrinsic, tissue-
dependent, way that increases with the number of stem-cell divisions, and a cell-extrinsic 
way that increases in line with the cumulative exposure to environmental risk factors (e.g. 
smoking, obesity mediated inflammation, viral infections)3,110-112. Both components increase 
with chronological age, and are intricately linked; cumulative exposure to cancer risk factors 
is thought to accelerate the stem-cell division rate of tissues110. In addition, DNA methylomes 
at the two extremes of the human lifespan (i.e. new-borns and centenarians) are distinct in 
the same subset of cells113. Like somatic mutations and copy number variations (CNVs), 
DNAme alterations gradually accumulate with chronological age114-116 and with exposure to 
cancer risk factors independently of age117. These factors are thought to reflect cell-intrinsic 
(e.g. stem-cell division) and cell-extrinsic (e.g. metabolically induced) factors contributing to 
the molecular damage of tissues. Thus, specific DNAme changes in the tissue of origin (or 
suitable surrogates), may be informative of cancer risk, as demonstrated in the context of 
cervical cancer118. Supporting this further, an epigenetic mitotic-like clock (“EpiTOC”)32, which 
correlates with the cumulative number of stem-cell divisions in the tissue of origin, is 
universally accelerated in cancer tissues and pre-neoplastic lesions, again offering promise 
for cancer-risk prediction32,118. In contrast, Horvath’s epigenetic clock, a tissue-independent 
non-mitotic clock which measures chronological age119,32, appears to be less informative with 
respect to cancer risk32,117. 
 
Current evidence from EWAS:  
There is substantial evidence for the existence of epigenetic field defects i.e. aberrant 
epigenetic signatures in normal tissue adjacent to the cancer60,120-123. Within EWAS a 
genome-wide set of quantifiable epigenetic marks (i.e. DNA methylation) in different 
individuals will be analysed with the aim of deriving associations between epigenetic variation 
and a particular identifiable phenotype/trait. Analogous to the genome-wide association 
studies (GWAS)124 we propose that a minimum of 100,000 CpGs per individual are analysed 
in order to apply the term “epigenome-wide”. When compared with GWAS, several additional 
challenges exist. Notwithstanding the correct choice of easy to access surrogate tissue, the 
modifiable character of epigenetic markers creates difficulties in discriminating between 
cause and consequence and must therefore be taken into account when considering the 
timing of the sample collection in relation to the manifestation of the disease. Unlike GWAS 
where variants at single nucleotide positions are associated with a specific trait, the basis of 
EWAS is to quantify methylation at CpGs across the genome in a given sample and rank 
these sites according to their different methylation levels between cases and controls. To 
date, both EWAS and studies looking at a predefined sets of CpGs have been performed.  
Two principal categories of epigenetic risk predictors exist. 
 Category 1 – DNAme markers of “extrinsic risk exposure”: These are DNAme markers 
that reflect exposure to specific exogenous carcinogens. The magnitude of the impact on 
DNAme reflects the individual response and acts as a surrogate marker for the development 
of cancer in an individual. For example, there is dose-dependency of methylation levels of 
CpGs in the AHRR or F2RL3 gene with smoking pack-years26,125 which is a quantitative 
measure of active lifetime tobacco exposure. Demethylation at the AHRR or F2RL3 CpG site 
(1st versus 4th quartile) was associated with a 16- and 11- fold increased risk for lung cancer 
respectively even after adjusting for a variety of factors including current smoking status and 
duration126,127. These findings have been validated by independent studies based on different 
cohorts128. Importantly, the top ten smoking–associated CpGs in blood surpassed the 
performance of the top ten lung-cancer-related CpGs in blood with regard to predicting lung 
cancer mortality129. To date, there is no clear evidence that aberrant methylation of AHRR 
observed in the surrogate tissue (i.e. blood or buccal cells) of smokers who are predisposed 
to lung cancer development actually drives cancer development in the tissue at risk (i.e. lung 
epithelial cells); functional work on AHRR methylation in lung cell models will need to be 
carried out. 
A recent EWAS demonstrated that BMI is associated with substantial DNAme changes in 
blood samples and that these associations are mainly a consequence of obesity, not the 
cause of it70. Obese individuals in the top quartile of the methylation risk score had a 10-fold 
increased risk of developing type 2 diabetes in the future compared with those in the lowest 
quartile70. The observation that genes involved in oestrogen response (e.g. in p53 and NF-
kB pathways) were enriched amongst the obesity-associated genes implies that an obesity-
associated DNAme signature is capable of predicting the incidence of obesity-associated 
cancers, irrespective of the actual individual BMI at the time of assessment. 
Epigenetic age acceleration (i.e. the deviation of epigenetic age from the actual chronological 
age) assessed in peripheral blood was associated with cancer incidence85 and mortality85,130 
in general and, specifically, with postmenopausal breast87 or lung86 cancer susceptibility. 
 
 Category 2 - DNAme markers of “intrinsic risk”: Most known DNAme markers predicting 
cancer risk have been discovered based on case control or population-based nested case 
control settings and have not as yet been linked to extrinsic risk factors.  
More than a decade ago, anecdotal reports131,132 provided initial evidence that DNA 
methylation of the mismatch repair gene MLH1 in normal cells is present in individuals with 
multiple cancers. Early reports indicated that loss of imprinting of IGF2 in lymphocytes is 
predictive of colorectal cancer risk133 but studies using DNAme in peripheral blood predating 
diagnosis could not confirm these findings134. 
The first large study (sample size larger than 1000 cases and controls) provided a direct link 
between DNAme of the oestrogen-receptor interacting ZNF217 gene, serum oestrogen 
receptor alpha bioactivity and breast cancer risk135. These data and the majority of data 
referenced in this section (apart from those referenced in Table 3) have been generated 
based on the analysis of biological material (i.e. surrogate tissue) derived from prevalent (i.e. 
already existing) cases; this comes with several challenges as outlined in the following 
example: The first study analysing a larger number of CpGs - approximately 25,000 CpGs 
(i.e. Illumina’s 27k methylation array) - was conducted in blood from ovarian cancer patients 
and non-cancer control women136 and concluded that the timing of sample collection for 
DNAme analysis and adjustment for sample cell-type composition is essential for valid 
interpretation of results (see chapter “Tissue specificity of the epigenome” for more details). 
Another study using the same assay derived a DNAme signature from the peripheral blood 
of BRCA1 mutation carriers, which was significantly enriched for PCGT hypermethylation and 
predicted breast cancer incidence and death independently of family history or other known 
risk factors137. 
To date, only a very limited number of studies have acknowledged the tissue specificity of 
the DNA methylome. The majority of ovarian cancers are derived from cells arising from the 
Fallopian Tube, the latter of which shares the same developmental origin as the 
endometrium. DNAme of HOXA9, a gene essential for differentiation of the Fallopian Tube, 
is substantially increased in the normal endometrium of ovarian cancer patients, but not in 
the adjacent myometrium, the non-epithelial component of the uterus44. 
In the context of cervical cancer screening, the uterine cervix is one of the very few organs 
that allows for the assessment of normal cells years in advance of the onset of any 
cytological/histological changes. A DNAme signature derived from cytological normal 
samples which predate a diagnosis of cervical intraepithelial neoplasia grade 2 or 3 (CIN2+) 
by three years118 discriminated cytologically normal cells from CIN2+ smears with a ROC 
AUC of 0.69-0.87 and a normal uterine cervix from an invasive cervical cancer with a AUC of 
0.94138. 
Numerous additional studies (all carried out in whole blood samples or a subset of blood 
cells) have found evidence of different global139 or gene specific DNAme in samples collected 
from testicular139, ovarian140,141, colorectal142, breast143,144, head and neck145, melanoma146,147 
and renal148 cancer patients and cancer-free controls. 
An increasing number of studies have identified and/or validated DNAme markers with the 
help of population based cohorts predicting the development of breast149-152, bladder153,154 or 
hepatocellular cancer155,156. 
 
Cancer prevention:  
Unlike genetic markers, epigenetic markers are modifiable and not only potentially indicate 
the risk of developing a certain cancer disease but, importantly, can also be used in 
monitoring the response to preventive measures. A study of 1,092 healthy female volunteers 
showed that the methylation rate of CpGs, related to colorectal cancer, show a reduced rate 
of methylation in individuals exposed to cancer-preventive drugs such as acetylsalicylic acid 
or hormone replacement therapy, and an increased rate of methylation in smokers and in 
women with high BMI157. The observation that time since cessation of smoking is reflected in 
the epigenome of easily accessible organs not primarily at risk for smoke-induced 
cancers26,158,159 indicates that it may be feasible to monitor preventive strategies for 
inaccessible organs by means of DNAme in easy to access samples. Besides smoking, 
DNAme changes associated with obesity have also been shown to be similar between 
adipose and blood cells70, further supporting this principle. Ongoing work will determine which 
easy to access surrogate tissue best reflects the epigenetic state in those organs at risk for 
which epigenetic field defects are likely drivers of carcinogenesis60,120 – this is a long-term 
requirement for effectively monitoring cancer-preventive measures. 
 
Tissue specificity of the epigenome: 
Although the specific tissue from which the cancer arises would be the ideal target for the 
retrieval of cells with an epigenetic risk signature, apart from a few exceptions (e.g. cervical 
smear for cervical cancer), it is not typically feasible to access the tissue at risk directly as 
this would require invasive procedures (e.g. bronchial lavage, biopsies of the breast, liver, 
pancreas, prostate, colon or Fallopian Tube). We therefore propose that surrogate tissue – 
from blood (i.e. normal blood cells), buccal and cervical cells (and possibly cells from urine) 
- to be used for this purpose. To date, the vast majority of analyses have been undertaken in 
blood cells as these samples are readily available in various cohorts (Table 3).  
The fact that the tissues used in EWAS represent complex mixtures of many underlying cell-
types whereas DNA methylation is cell-type specific160,161, poses a significant challenge to 
the analysis and interpretation of EWAS data162, not encountered in GWAS. For instance, 
many cancer EWAS conducted in whole blood and peripheral blood have demonstrated that 
most DNAme changes between cancer cases and controls can be attributed to shifts in the 
granulocyte/monocyte to lymphocyte proportions, reflecting a specific and major immune-
response to the presence of cancer145,154,163,164. In women with primary ovarian cancer or 
residual disease after chemotherapy, such shifts in DNAme provided highly accurate 
predictions of cancer-status (AUC>0.8)164. However, when assessing ovarian cancer patients 
who had undergone chemotherapy and who did not have evidence of residual disease 
(ovarian cancer serum marker CA125 < 35 U/mL), DNAme profiles were largely 
indistinguishable from age-matched controls164. While DNAme changes associated with such 
shifts in cell-type composition could be useful for general diagnostic purposes, they do not 
represent epigenetic alterations which may potentially drive carcinogenesis. Identifying the 
latter requires the inference of differentially methylated CpGs (DMCs) that are not driven by 
underlying changes in cell-type composition. To help address this challenge, efforts such as 
the IHEC165 and BLUEPRINT166 are underway generating reference DNAme profiles for all 
major human cell-types. These reference DNAme profiles, although derived from specific 
individuals (and thus potentially confounded by factors such as genotype and age), can be 
used in the deconvolution of bulk-tissue DNAme profiles167, providing reasonably accurate 
estimates of underlying cell-type proportions in independent samples, as confirmed using 
matched FACS/MACS-based cell count data168 (Figure 3). These cell-type fraction estimates 
can subsequently be used to adjust the DNAme data, allowing identification of DMCs that are 
not driven by changes in cell-type composition167,168. Using this approach, a recent meta-
analysis of solid cancer EWAS conducted in blood, further confirmed that very few of the 
DMCs between cancers and controls remain after adjustment for cell-type composition153. 
Although these residual DMCs were found to map to cancer-related pathways153, their 
interpretation and relevance for the corresponding cancer-type is still unclear. It is likely that 
further progress will require the identification of DNAme changes in either the cell of origin of 
the cancer, or in surrogate tissue/cells that more closely represent the cell of origin in 
epithelial cancers. Ongoing work will demonstrate whether a combination of the epigenomes 
in several surrogate tissues [i.e. blood (capturing the contribution from the stroma/immune-
system), cervical and buccal cells (capturing the hormone dependent and independent risk 
factors, respectively)] might provide the best accuracy. 
 
Cell-free DNA in serum or plasma is currently used to monitor the efficacy of cancer treatment 
and identify therapy-resistant cancer clones. In this context, somatic genetic or epigenetic 
alterations which have accumulated in the established cancer and are released into the liquid 
phase are analysed (i.e. “liquid biopsy”). This, by definition, is not useful for cancer-risk 
prediction as discussed in the context of this review. However, having said this, there is now 
some preliminary evidence that organ-specific DNAme patterns can be detected in cancer-
free individuals169,170. Whether this cell-free DNA in plasma/serum can be used to assess 
future cancer-risk for specific organs needs to be determined once sufficiently large 
population-based cell-free DNA repositories (which are not massively contaminated with 
DNA released from blood cells) have become available and their donors followed up for a 
sufficient amount of time in order to identify those individuals who eventually developed a 
cancer. 
 
In summary, tissue specificity is a hallmark of the epigenome. The vast majority of EWAS 
studies have been performed based on peripheral blood cells. To date, not one study has 
analysed several surrogate tissues (i.e. blood cells and buccal) from the same individuals at 
the same time in order to assess which surrogate tissue is best suited to predict future risk 
for a specific cancer entity. Thus far, it is also unclear whether epigenetic profiles in blood 
cells (i.e. the vast majority of EWAS were based on blood epigenomes) are (i) a surrogate of 
the epigenome in the tissue at risk or (ii) purely an indication of the epigenetic status of 
immune-cells (and thereby reflective of their anti-neoplastic capacity) or a combination of (i) 
and (ii). Limited data correlating blood epigenomes with those of various regions of the brain 
from the same individuals only found  rather weak correlations indicating that the blood 
epigenome only very weakly reflects the brain’s epigenome 171. 
 
 
 
Translational Challenges:  
The development of epigenome-based risk predictors in surrogate tissues face several 
significant challenges.  
 
Choice of DNAme analysis method: 
Box 1 describes the potential tools for discovering DNAme risk predictors and for clinical 
application of these markers. The choice of tool will depend on the size and costs of the study, 
the heterogeneity of the samples as well as whether quantitative assessment of single CpG 
methylation or DNAme patterns in a specific region is required. 
 
Choice of surrogate tissue: 
Although recent studies have indicated that cancer risk prediction may be possible using 
DNAme profiles obtained in blood86,172, prediction accuracies are low, and require further 
validation and have an unclear mechanistic basis. In the context of women-specific cancers, 
cervical smears, representing hormone-responsive tissue, are a more promising alternative. 
Cervical smears may serve to identify relevant epigenetic cancer-risk biomarkers not only for 
cervical cancers but also for endometrial and ovarian (due to their common embryological 
origin) as well as breast (hormonally-triggered) cancers in prospective case/control settings 
nested within larger prospective clinical trials. Buccal cells (epithelial cells directly exposed 
to smoke-toxins) may be the best surrogate tissue for predicting lung cancer risk and a urine 
sample containing epithelial cells from the urethra (the prostate’s embryological origin) might 
be best suited for predicting prostate cancer risk.  
 
Analytical challenges 
The identification of DNAme alterations that may indicate cancer-risk is particularly 
challenging since the relevant comparison is between normal cells at risk and normal cells 
that are not. Such normal to normal tissue comparison is statistically challenging118 owing to 
(i) technical confounders, (ii) biological confounders (e.g. cell-type heterogeneity), and (iii) 
the likely stochastic nature of DNAme changes preceding carcinogenesis.  
Although technical confounders (e.g. batch effects) are frequently observed in -omic 
datasets173, there are also many statistical algorithms that can successfully be used to adjust 
data for these confounders174,175,176. Cervical smears, comprising various types of epithelial 
and immune cells, exhibit substantial variation in immune-cell fractions between unrelated 
women, making adjustment vital. Statistical methods, specifically designed for cell-type 
composition, have also been developed167,177 and allow for the identification of DMCs not 
driven by changes in tissue composition (Figure 3). 
In the context of cancer risk prediction, an additional statistical challenge arises because 
differences between normal cells and normal cells at risk of neoplastic transformation are 
expected to be infrequent and stochastic, which means that standard algorithms based on 
selecting DMCs may fail118. While cancer cells exhibit widespread changes in DNAme which 
are identifiable using DMC approaches and account for most of the variation in the data17,120, 
precursor cancer cells exhibit a much more heterogeneous and stochastic pattern118,178. This 
is possibly due to normal cells not having undergone neoplastic transformation and 
consequently not being selected for. A recent proof-of-principle study, conducted in the 
context of cervical cancer, confirmed the aforementioned118; it demonstrated that the DNAme 
patterns of normal cervical smears from women who developed a CIN2+ lesion three years 
after sample collection could only be distinguished from those of women who remained 
(pre)cancer-free and only if one adopts a radically different statistical feature selection 
paradigm which selects for CpGs with heterogeneous and stochastic patterns, the so called 
Differentially Variable CpGs (DVCs). Such DVCs manifest as outlier DNAme events that are 
only seen in a very small fraction of the women who later developed CIN2+. While DVCs 
appear to be stochastically distributed across independent individuals, the pattern is 
distinctively non-random across the genome of any individual, highlighting that there are 
specific regions of the genome that are more susceptible to inter-individual variation in 
DNAme, as previously observed118,179-181. Thus, as shown in the context of cervical 
carcinogenesis118, risk prediction may be possible by measuring the accumulation of 
deviations in DNAme from the normal state across a well-defined set of DVC loci, an 
approach called EVORA (Epigenetic Variable Outliers for Risk prediction Analysis)118,182. 
While the EVORA framework awaits further validation, independent strong evidence for its 
validity was obtained recently in the context of breast cancer, by comparing normal breast 
tissue from women to the normal breast tissue adjacent to breast cancers178: EVORA could 
distinguish normal tissue from breast cancer patients from that of healthy women with an 
AUC of 0.84. 
 
Sample size: 
The search for epigenomic risk markers is often hampered by the analysis of relatively small 
sample sets, caused by high costs. Consequently, spurious associations between CpGs and 
cancer risk may be found, and true associations may be exaggerated. The ideal scenario of 
comprehensive data from a single large-scale, prospective cohort study may not be reached. 
The evidence-base for associations may be increased by also considering results from other 
prospective study designs that include only incident cases, matched to well-defined, 
population-based controls (Table 3). Such studies allow unbiased estimation of relative risks. 
Applying simulations for EWAS183 and calculations based on our data26,118,120,121,137 suggest 
that 300 cases and 300 controls are sufficient to discover differentially methylated CpGs. 
Validation studies with independent, population-based data are required to confirm any 
associations and to validate absolute risks that apply to the general population. 
 
Data storage and sharing:  
Adopted by the European Union in 2016 and coming into effect in 2018, the General Data 
Protection Regulation (GDPR)184 provides legal guidance for the management of privacy risks 
based on the data types (e.g. personal data, genetic data, data concerning health, biometric 
data or sensitive data), levels of identifiability (anonymous, pseudonymised or identifiable 
data) and data uses (e.g. clinical care, research). While anonymous data fall outside the 
purview of the GDPR, sharing of pseudonymised (e.g. coded) and identifiable data is strictly 
regulated. 
Therefore, in the context of the epigenetic risk prediction test, the main challenge for the 
scientific community would appear to be characterising the identifiability of epigenomic 
information. Does epigenomic information allow for the identification of a natural person, 
directly or indirectly? Should it be considered as ‘personal’, ‘sensitive’, ‘genetic’ or health-
related information? Such questions are key when addressing the specific issues raised by 
sharing epigenomic information.  
 
Challenges to implement epigenome-based risk predictors as a clinical tool: 
Combining genetic variants with environmental and lifestyle risk factors would improve risk 
stratification. The use of epigenetic changes captures the interaction of observed and 
unobserved risk factors at each individual’s cellular level185, while the assessment of these 
risk factors via questionnaires and retrospective self-reporting is of limited reliability and 
susceptible to, for example, recall bias186.  
 
The implementation of risk-tailored cancer prevention and early diagnostic programmes is a 
multi-step process and raises a number of challenges for policymakers and the public they 
serve (Figure 4). The organisational challenges to be addressed include providing equitable 
access to risk assessment and risk-tailored interventions, preparing and training the 
workforce, building an infrastructure for assessing the quality of tests and services, and 
developing IT platforms and data storage capacity. Using epigenome-based risk assessment 
poses additional organisational challenges due to the plasticity of the epigenome that 
requires repeated risk assessment over time and varying intervention recommendations 
according to risk levels. Based on the available data on smoking and methylation (i.e. DNAme 
changes as a function of accumulating pack-years and of time after cessation of 
smoking26,158) we speculate that an epigenetic risk predicting test will have to be repeated 
every 3-5 years in order to re-calculate the risk.  
 
Ethical issues: 
The epigenome acts as a surrogate readout for heritable and lifestyle factors, raising 
several issues: (i) Personal responsibility and healthy lifestyle; how much responsibility can 
be attributed to the individual and to what extent individuals can be held accountable for 
their health? (ii) Safeguarding autonomous decision-making; how to guarantee that 
individuals are making a voluntary and well-considered informed choice for or against a 
test comprising complex information about risks for different diseases with varying ages of 
onset. (iii) Risk profiles for one cancer might encapsulate information for other conditions. 
For example signatures for cervical or breast cancer might reflect the individual response 
to smoking and obesity and as such also indicate the risks for lung cancer126-128,158 or type 
2 diabetes70, respectively. This requires new informed consent paradigms (e.g. tiered, 
staged models)187, shared decision-making and novel patient decision tools in a clinical as 
well as in a population screening context188. Further, implementation of epigenome-based 
risk predictions in the latter context involves reinterpreting current ethics frameworks of 
population screening. 
 
Legal issues: 
The development of genomics and other -omics sciences, including epigenomics, has eroded 
the once clear boundary that existed between research and clinical care. This new 
‘’translational’’ space is conducive to improving healthcare but also raises legal issues due to 
the reversibility of epigenetic risk factors and the dynamic, sometimes transgenerational, 
nature of epigenetic data. Relevant legal issues include: (i) Consolidation of a cost-efficient 
pathway for regulatory approval of new epigenetic tests. (ii) Clarification of the limits of liability 
for researchers and clinicians (e.g. when returning research results or incidental findings, 
including epigenetic test results to the medical file, and updating patients on important 
changes in epigenetic material). (iii) Clarification of privacy and confidentiality rights of the 
patient vs. those of family members (e.g. siblings, children, etc.); and (iv) Promotion of 
equality while promoting the data sharing necessary for advancing epigenetic science189. 
 
Risk communication: 
To assess the risk of individuals requires informed consent and the provision and 
communication of evidence-based information in lay language. Some of the communication 
challenges associated with epigenome-based risk assessment are identical to already 
existing tests. Individuals need to be informed upfront (e.g. by fact boxes190) concerning their 
age-adjusted baseline risks, the benefit-harm-ratio of having or not having the test, and the 
modified benefit-harm ratios of current cancer screening approaches and prevention as a 
consequence of the test191. Epigenetic screening, however, has additional layers of 
complexity; individuals need to be informed about the complex cancer-specific interplay of 
genes, environment, and behaviour and additionally that testing for epigenetic factors will 
reveal some of their past environmental exposures (i.e. smoking, alcohol, etc.). It will 
therefore be essential that the healthcare workforce is trained in interpretation192-195 and 
communication of risk prediction test results. 
 
Decision analysis to evaluate the relationship between benefits and harms: 
Scientific evidence needs to demonstrate additional benefit for a new risk-tailored screening 
or prevention strategy, with an acceptable benefit-harm ratio and cost-effectiveness ratio 
when compared to current standards of care196-198. Decision-analytic modelling is a useful 
quantitative approach for synthesising the best available scientific evidence such as 
epidemiologic parameters, test performance, prognosis, treatment effectiveness, quality of 
life, and economic data. It is also useful to evaluate the trade-off between benefits, harms, 
and costs of alternative interventional strategies199-201. Decision-analytic models simulate the 
development of the disease, and the consequences of different screening/prevention 
strategies including specific medical pathways200,202 (Figure 5).  
 
Adaptation of the currently established infrastructure: 
The leveraging of already existent screening programmes is a key opportunity for rapid 
real-life evaluation and roll-out of new tests. In most high-resource settings, the 
infrastructure for cancer screening programmes is already available and could be used for 
new -omic frontiers in prevention. Such programmes have the inherent potential to test new 
biomarkers through so-called randomised health services studies (RHS;203). Once 
evaluated by a RHS design, new screening tests – if found to be superior to the old policy 
– could be immediately implemented since the programme has already been part of the 
testing phase. 
 
Conclusions and future directions: 
Epigenetic based risk models provide state-of-the-art opportunities for personalised medicine 
and risk-level-tailored interventions to improve human health through the reduction of cancer 
burden. Although several significant challenges have been identified and further research is 
required, such risk models are potentially feasible and, when available, would likely meet 
most criteria needed for effective risk prediction, i.e. the ability to:  
(i) encapsulate both genetic and non-genetic risk referring factors using a single -omics 
platform which is biologically stable and technically reproducible;  
(ii) derive a predictive score using easily accessible tissues which are relevant for cancer 
development or are able to capture risk-referring signals; 
(iii) be used to monitor the efficacy of risk reducing measures. 
Development and implementation of epigenomic-based cancer prevention and 
screening/early detection programmes requires international collaboration between 
multidisciplinary teams with expertise in -omics, bioinformatics, epidemiology, public health, 
economics, decision analysis, ethics, law, risk communication and engagement of the 
scientific community with healthcare professionals, policy makers, and the public. In order to 
develop epigenomic-based cancer prevention, multidisciplinary research through 
international consortia is needed to overcome the various scientific challenges.  
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TABLES:  
 
Table 1. Percentage of variance in liability for several common cancers. 
Disease is assumed to arise from a liability threshold model, in which each individual has an 
unobserved, normally distributed liability that results in disease when it exceeds a threshold. 
Heritability; variance explained by heritable factors, estimated from twin or family studies. 
Known genes; variance explained by established risk genes including findings from genome-
wide association studies. Environmental, variance explained by environmental exposures.  
 
 Percentage of Variance (95% CI) 
Cancer Heritability Known genes Environmental 
 
    
Ovary6,204 22 (0-41) 1 (1-1) 78 (59-100) 
 
Endometrium6,205 24 (14-87) 0 (0-0) 76 (13-86) 
 
Lung6,204 26 (0-49) 2 (2-2) 74 (51-100) 
 
Breast6,204 27 (4-41) 8 (0-21) 73 (59-96) 
 
Cervical206,207 27 (26-29) 2 (0-5) 78 (71-74) 
 
Colorectal204,208 35 (10-48) 1a (1-1) 65 (52-90) 
 
Pancreas6,204 36 (0-53) 2 (2-2) 64 (47-100) 
 
Kidney6,205 38 (21-55) 3 (3-3) 62 (45-79) 
 
Prostate6,204 42 (29-50) 22 (0-93) 58 (50-71) 
 
Melanoma6,205 58 (43-73) 9 (9-9) 42 (57-27) 
 
a converted from recurrence risk to liability scale using formula given by Wray et al209 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Examples of currently recognised and validated risk prediction models. 
 
a Performance at external validation 
b Performance at internal validation 
AUC, Area Under the ROC Curve. 
 
Cancer type 
and/or 
model 
Phase 
(development/ 
validation/impact 
assessment) 
Endpoint 
(any cancer 
/progressive 
cancer) 
Predictors included in the final 
model 
Discriminative 
ability 
(AUC) 
     
Breast210 
IBIS model 
 
Validation Any 
 
Age, BMI, age at menarche, age at 
first birth, age at menopause, no. of 
breast biopsies, atypical 
hyperplasia, lobular carcinoma in 
situ, family history of breast/ovarian 
cancer 
0.76a 
Ovarian211 
 
Validation 
 
Any 
 
 
Age, Oral contraceptive use, 
menopausal hormone therapy use, 
parity, family history of 
breast/ovarian cancer 
0.59a 
 
Cervical11 
 
Development  CIN1/CIN2+ High DNA-load of high-risk HPV, 
age, married status, smoking, age at 
sexual debut 
0.76 CIN1b,  
0.90 CIN2+b 
Prostate212 
ERSPC risk 
calculator 
Impact 
assessment 
Any Ultrasound volume, digital rectal 
exam, transrectal ultrasound, PSA 
0.76a 
Lung213 
PLCOM2012 
model 
Validation 
 
Any 
 
Age, race, education, BMI, COPD, 
personal history of cancer, family 
history of lung cancer, smoking 
status, smoking duration, smoking 
intensity, years since cessation 
0.69-0.79a 
Esophageal21
4 
Validation Any 
 
age, sex, smoking status, body 
mass index, highest level of 
education, frequency of use of acid 
suppressant medications  
0.61a 
Colorectal215 Validation Any 
 
Sigmoidoscopy results, 
colonoscopy results, history of 
polyps, relative with CRC, 
aspirin/nonsteroidal anti-
inflammatory drug use, smoking, 
vegetables, body mass index, 
leisure time activity (men only), 
leisure exercise time (women only), 
oestrogen status (women only) 
0.61a 
  
 
 
 
 
 
 
Table 3. Studies predicting risk for incident cancers using DNAme markers.  
Only studies using population–based samples with incident cancers (i.e. volunteers cancer-free at the time of sample collection) were used irrespective 
of how many CpGs were analysed. AUC = Area under the curve. CI = Confidence interval. HCC = hepatocellular carcinoma. HR = Hazard ratio. OR 
= Odds ratio. 
 
Cancer  Source of 
DNA 
Technique Markers Numbers Remarks 
 
Adjusted for cell type 
composition 
Study Design 
        
Breast152 Blood Bisulfite 
pyrosequencing 
ATM 640 cases,  
741 controls 
Top quintile of methylation 
associated with  
OR 1.89 for breast cancer (95% 
CI1.36–2.64; P = 1.64 × 10−4) 
Not adjusted for cell 
type composition 
Nested case-
control/case-
control 
Breast151 Blood Illumina  
27k array 
250 CpGs 298 cases,  
612 controls 
AUC 0.66 for breast cancer 
(95% CI 0.61-0.71)  
Not explicitly adjusted 
for cell type 
composition? 
Nested case-
cohort 
Breast137 Blood Illumina 27k  
& 450k array 
1829 CpGs 210 cases,  
271 controls 
AUC 0.67 for fatal breast cancer 
(95% CI 0.51 to 0.83; P = 0.02) 
Not corrected for cell 
type composition 
Case-control 
Breast149 Blood Illumina  
450k array 
mean beta 
values 
across all 
CpGs  
420 cases,  
420 controls 
OR for breast cancer was 0.42 
(95 % CI 0.20–0.90) for the top 
quartile of epigenome-wide DNA 
methylation 
Analysis of dried blood 
spot samples adjusted 
for the predicted cell-
type composition 
Nested case-
control 
Breast150 Blood Illumina  
450k array 
mean beta 
values 
across all 
CpGs  
358 cases,  
358 controls 
Top quartile of methylation 
associated with ORs 0.34 (95% 
CI (0.18–0.66) and 0.99 (95% CI 
(0.56–1.76) for breast cancer in  
2 out of 3 studies 
WBC differentials not 
available but two other 
methods used to infer 
cell proportions 
Nested case-
control 
Breast87 Blood Illumina  
450k array 
353 CpG  
age 
signature 
451 cases,  
451 controls 
1 unit increase of epigenetic age 
acceleration associated with 4% 
increased odds for breast 
cancer (OR=1.04, 95% CI 
(1.007–1.075, p=0.016)  
Adjusted for seven 
measures of blood cell 
count abundances 
Nested case-
control 
Lung86 Blood Illumina  
450k array 
353 CpG  
age 
signature 
43 cases,  
1986 controls 
1 unit increase of epigenetic age 
acceleration associated with 
50% increased lung cancer risk 
(HR: 1.50, p = 3.4×10−3) 
Adjusted for 
abundance measures 
of blood cell counts 
Case-control 
Lung158 Blood Illumina  
450k array 
AHRR, 
F2RL3 
789 cases,  
789 controls 
AUC 0.76-0.78 adjusted for 
smoking 
Adjusted for blood cell 
composition 
Nested case-
control/case-
control 
Lung216 Blood MassARRAY F2RL3 318 cases,  
4669 controls 
AUC 0.77 (95% CI 0.72-0.81) Not adjusted for cell 
type composition 
Cohort study 
Lung126 Blood Bisulfite 
pyrosequencing 
AHRR, 
F2RL3 
143 cases,  
453 controls 
Bottom quartiles of DNAme of 
AHRR and F2RL3 associated 
with ORs of 15.9 (95% CI 4.2–
60.2) and 10.56 (95% CI 3.4–
32.3), respectively adjusted for 
smoking and other factors 
Not adjusted for 
leukocyte composition 
Nested case-
control 
Lung127 Blood Real time PCR AHRR 352 cases,  
8859 controls 
Bottom quintile of methylation 
associated with HR=4.9 (95% CI 
2.3 - 10.3) for lung cancer  
Not adjusted for cell 
type composition 
Cohort study 
Cervical 
(pre-
invasive)118 
Cervical Illumina 27k 
array 
140 CpGs 77 incident 
CIN2+ cases 
EVORA  algorithm showed high 
sensitivity and specificity to 
detect pre-invasive neoplasia 
Not adjusted for cell 
type composition 
Nested case-
control 
and 77 
controls 
and cervical cancer (AUC = 0.93 
(0.86 to 1) and AUC = 1, 
respectively) 
Liver156 Blood MethyLight, 
Bisulfite 
pyrosequencing 
Sat2,  
LINE-1 
305 cases,  
1254 controls 
A 1 unit decrease in logSat2 1 
methylation associated with an 
adjusted OR for HCC of 1.77 
(95% CI 1.06–2.95). 
Not adjusted for cell 
type composition 
Nested case-
control  
Liver155 Blood Illumina  
450k array 
WNK2,  
TPO, MYT1L 
159 cases,  
312 controls 
ORs for HCC (methylation 
above vs below median) = 1.91 
(95%CI: 1.27-2.86 for WNK2); 
0.59 (95%CI:0.39-0.87 for TPO), 
and 0.50 (95% CI 0.33-0.77 for 
MYT1L), respectively 
Not adjusted for cell 
type composition 
Nested case-
control  
Various85 Blood Illumina  
450k array 
71 CpG age 
signature 
132 cases, 
310 controls (2 
samples from 
most 
volunteers) 
One year increase of epigenetic 
compared to chronological age 
associated with 6% increased 
cancer and 17% mortality (HR: 
1.06, 95% CI: 1.02–1.10 and 
HR: 1.17, 95% CI: 1.07–1.28, 
respectively). 
Adjusted for changes 
in white blood cell 
composition and 
immunosenescence 
Cohort study 
 
BOX: 
 
Box 1| Potential methods for the assessment of the DNA methylome for risk 
predicting purposes 
 
The majority of technologies used to quantify DNA methylation rely on the principle of 
sodium bisulfite-induced deamination of unmethylated cytosine to uracil, followed by either 
microarray or sequencing as a read-out. 
 
For discovery (i.e. feature selection): 
 Whole Genome Bisulfite Sequencing (WGBS): A labour intensive method involving 
DNA fragmentation, ligation of adapters, purification of ligation products, bisulfite 
modification (BM), polymerase chain reaction (PCR), and sequencing. Theoretically, 
WGBS is able to capture all CpGs in the genome at single nucleotide resolution. 
 Reduced Representation Bisulfite Sequencing (RRBS): Sequencing method that 
enriches for CpG rich regions of the genome, by digesting genomic DNA with Msp1. 
RRBS covers 85% of CpG islands and 60% of promoters. Steps involve DNA digestion, 
end-repair, A-tailing, adapter ligation, fragment size selection, BM and sequencing. 
 Methylation Arrays: Arrays targeted to the methylated regions (CpG islands) of the 
genome. The Methylation EPIC BeadChip (Illumina5), covers 99% of RefSeq genes and 
95% of CpG islands and allows interrogation of >850,000 methylation sites. Arrays also 
rely on BM but is less labour-intensive than sequencing. 
 Affinity Enrichment methods: Based on the affinity purification of methylated DNA 
regions using either an antibody directed against 5-methylcytosine (MeDIP6) or against 
methyl-binding proteins (MethylCap7). Isolated methylated DNA can be assessed by 
PCR, microarray or sequencing. 
 
For clinical assays: 
Clinical assays require a targeted approach, allowing for the screening of large sample sets 
but only covering the regions of interest. This allows for a reduction in work-load and over-
all cost. 
 Custom Arrays: Specific regions of the genome can be studied with custom designed 
arrays. Various companies (Illumina, Agilent, Roche) offer custom array services for the 
creation of targeted assays.  
 Targeted Bisulfite Sequencing: Use of specifically designed primers and NGS 
technology for the analysis of targeted genomic regions of interest. Cost per sample is 
reduced, but single nucleotide resolution is maintained.  
 Pyrosequencing: DNA sequencing based on the "sequencing by synthesis" principle. It 
relies on the detection of pyrophosphate release upon nucleotide incorporation. A light 
signal is generated that allows for quantitative methylation analysis. 
 Quantitative PCR: Amplification of BM-DNA with fluorescent primers that hybridise to 
predefined methylated regions, such as, in Methylight or digital PCR. 
 
 
 
 
 
 
 
 
FIGURES: 
 
 
Figure 1. Multicellular epigenetic risk predictor. Factors that trigger epigenetic mis-
programming in the inaccessible “tissue at risk” can be assessed in easily accessible 
“surrogate tissues”. ncRNA, non-coding RNA; HOTAIR, HOX transcript antisense RNA; 
H3k27, histone 3 lysine at position 27; Suz12, Suppressor of Zeste 12; EED, embryonic 
ectoderm development; EZH2, Enhancer of zeste homolog 2 histone-lysine N-
methyltransferase enzyme. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 2. Examples illustrating how epigenetic alterations contribute to cancer 
development. (A) A general, epigenome-genome unifying concept of cancer formation: 
Accumulation of epigenetic alterations as a function of stem cell divisions may fix stem-ness, 
a state which is compatible with genotoxicity-induced DNA damage leading to cancer 
formation. (B) A specific example of epigenome-mediated cancer formation: Functional 
oestrogen dominance in epithelial cells due to epigenetic silencing of essential progesterone 
downstream gene HAND2 in the endometrial stromal cells lead to precancerous complex 
atypical hyperplasia. E, oestrogen; P, progesterone; FGF, fibroblast growth factor; ERK, 
extracellular signal regulated kinase.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. The use of the epigenome in adjusting for sample heterogeneity. (A) Depiction 
of the potential cellular heterogeneity within a complex cervical smear sample. (B) Cell type 
specific DNAme signatures (x-axis) are used to predict the actual proportion of cell subtypes 
in a sample verified by FACS analysis (y-axis); the examples are given for granulocytes and 
CD4 lymphocytes in blood samples.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 4. Organisational, ethical, legal and social issues (ELSI) to be considered when 
implementing epigenome-based risk predictors. ‘Key ELSI’ for risk-stratification based on 
the genome have already been identified by the COGS consortium217 and ‘Novel ELSI’ are 
additional issues for the Women’s cancer risk IDentification test (WID-test) specific to 
epigenome-based risk prediction tests.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Decision-analysis to evaluate the consequences of the DNA methylation 
(DNAme) test-based intervention strategies. NPV, negative predictive value; PPV, 
positive predictive value. 
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